Conclusions
“ASAP Scoring System and risk table” may provide additional
information to urologist for assessment of clinical options in patient
with ASAP. Total PSA, fPSA, f/tPSA rate and PSA-D levels may be
routinely evaluated in the patients with ASAP before the second biopsy
(4-6 weeks after the first biopsy). Alterations in these parameters may
be considered and accordingly, a re-biopsy decision may be made. The
risk group classification of patients by using of ASS-RT may help to
better define the patients who need to perform a second biopsy. Thus,
early diagnosis possibility for high risk patients will be possible. It
should be known that we also need more data to validate this scoring
system and risk table.